Showing 5801-5810 of 8158 results for "".
- Syneron Receives FDA Clearance to Market the Ultrashape System for Fat Cell Destructionhttps://practicaldermatology.com/news/20140414-syneron_receives_fda_clearance_to_market_the_ultrashape_system_for_fat_cell_destruction/2459273/
- Frost & Sullivan Commends Sensus for the Development of SRT-100™ and SRT-100 Vision™, its Low-energy Radiation Therapy Systems for Treating Skin Cancerhttps://practicaldermatology.com/news/20140331-frost__sullivan_commends_sensus_for_the_development_of_srt-100_and_srt-100_vision_its_low-energy_radiation_therapy_systems_for_treating_skin_cancer/2459289/Based on its recent analysis of the non-melanoma skin cancer therapy market, Frost & Sullivan recognizes Sensus Healthcare LLC with the 2014 North American Frost & Sullivan Award for New Product Innovation Leadership. Sensus uses a technique known as superficial radiation therapy (SRT) in its two lo
- Dr. Zein Obagi to Introduce New ZO Skin Health Treatment Systems At The 2014 AAD Annual Meetinghttps://practicaldermatology.com/news/20140306-dr_zein_obagi_to_introduce_new_zo_skin_health_treatment_systems_at_the_2014_aad_annual_meeting/2459323/
- Steroids Found to be Widely Prescribed by Dermatologists for Psoriasis Managementhttps://practicaldermatology.com/news/20140220-steroids_found_to_be_widely_prescribed_by_dermatologists_for_psoriasis_management/2459337/
- New JAAD Study Offers Tips for Preventing and Detecting Skin Cancer in People of Colorhttps://practicaldermatology.com/news/20140206-new_jaad_study_offers_tips_for_preventing_and_detecting_skin_cancer_in_people_of_color/2459347/
- Ipsen Announces Clinical Results of Dysport Next Generationhttps://practicaldermatology.com/news/20140205-ipsen_announces_clinical_results_of_dysport_next_generation/2459348/
- Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Millionhttps://practicaldermatology.com/news/20140203-valeant_pharmaceuticals_to_acquire_precision_dermatology_for_475_million/2459351/
- FDA Approves Celluma as OTC Light Therapy Device to Treat Acne and Morehttps://practicaldermatology.com/news/20140121-fda_approves_celluma_as_otc_light_therapy_device_to_treat_acne_and_more/2459366/
- Merz Dermatology Announces Enhanced Naftin Co-Payment Savings Programhttps://practicaldermatology.com/news/20140117-merz_dermatology_announces_enhanced_naftin_co-payment_savings_program/2459370/
- NeXeption, LLC Forms New Company Alexar Therapeutics, Inc. to Develop Novel LXR Agonist Portfolio for Dermatologic Indicationshttps://practicaldermatology.com/news/20140102-nexeption_llc_forms_new_company_alexar_therapeutics_inc_to_develop_novel_lxr_agonist_portfolio_for_dermatologic_indications/2459383/NeXeption, LLC, a biopharmaceutical management company that brings together product opportunities, management expertise and funding to reach compelling partnership milestones, has secured $21.5 million in Series A financing to form Alexar Therapeutic